Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Nephrotic syndrome Stories

2014-01-31 10:46:34

In patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis. The findings, which will appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that this drug may provide considerable benefits for patients. For most...

2013-12-11 08:29:25

ANAHEIM, Calif., Dec. 11, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about January 24, 2014 to shareholders of record at the close of business on January 17, 2014. The Company also announced today that it made open market purchases during the fourth quarter of 2013 of approximately...

2013-12-05 20:22:12

ANAHEIM, Calif., Dec. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Oppenheimer 24th Annual Healthcare Conference in New York City on December 11, 2013 at 8:20 AM ET/5:20 AM PT. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor...

2013-11-22 08:23:12

-- Company recognized at NephCure annual "Countdown for a Cure" fundraiser ANAHEIM, Calif., Nov. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that the company has been recognized with an "Everyday Hero" award from the NephCure Foundation for its "tireless efforts" to advance science and research in the field of nephrology and to also promote educational efforts related to the treatment of proteinuria in patients with kidney disease who are suffering...

2013-11-07 08:31:13

ANAHEIM, Calif., Nov. 7, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the 2013 Credit Suisse Annual Healthcare Conference in Scottsdale, AZ on November 14, 2013 at 8:00 AM PT/11:00 AM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor...

2013-10-22 08:31:25

ANAHEIM, Calif., Oct. 22, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar® Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). The Company's Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active. ARDS is an acute life-threatening lung condition...

2013-10-10 08:28:38

Dividend Increased to $1.20 per Share on an Annual Basis ANAHEIM, Calif., Oct. 10, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis), reflecting a 5 cent or 20 percent increase over the previous quarter's dividend, and a 50 percent increase year over year. The dividend will be paid on or about October 30, 2013 to shareholders of record at...

2013-10-08 08:28:23

ANAHEIM, Calif., Oct. 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release third quarter 2013 financial results on Tuesday, October 29, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 29, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.. The call can be...

2013-09-23 23:34:17

Although Acthar Gel has numerous indications and data suggest that it may be a viable treatment option for resistant nephrotic syndrome, there remains a lack of guidelines on its use. Portland, OR (PRWEB) September 23, 2013 During a recent webinar hosted by AllMed Healthcare Management, Dr. James Wood, board-certified internist and nephrologist, gave an in-depth presentation on the use of Acthar Gel for the treatment of nephrotic syndrome. Although Acthar Gel has numerous indications and...

2013-09-05 08:28:14

ANAHEIM, Calif., Sept. 5, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will host investor meetings and will be a participant in a fireside chat session at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. The Conference does not accommodate formal presentations or the use of slides so there will not be a webcast presentation. About Questcor Questcor...